Why the study?
Although T2DM confers an increased risk of myocardial infarction, the role of APOA1 and APOB gene polymorphisms as genetic markers in a Mexican population required investigation.
Does the presence of APOA1 (-75 G>A and 83 C>T) and APOB (2488 C>T) polymorphisms increase the risk of myocardial infarction and alter lipid profiles in patients with Type 2 Diabetes Mellitus?
Does the presence of APOA1 (-75 G>A and 83 C>T) and APOB (2488 C>T) polymorphisms increase the risk of myocardial infarction and alter lipid profiles in patients with Type 2 Diabetes Mellitus?
APOA1 -75 G>A may signal elevated MI risk in T2DM; hypothesis-generating and requires replication before any clinical use.
Introduction The increased risk of myocardial infarction (MI) in T2DM is well documented. Polymorphisms in APOA1 and APOB genes allow us to identify new genetic markers in Mexican population with T2DM and MI. Material and methods We studied 135 patients with DMT2 and MI (DI); another 85 non-infarcted diabetic individuals with DMT2 but without previous ischemic events (NID) and 242 Healthy subjects (HS), all three groups were selected with the aim to investigate the association between the polymorphisms and infarction when T2DM is present or absent. Results -75 G>A polymorphism: differences were found in genotype distribution between DI and NID individuals (OR: 2.01, CI:1.117-3.623, p= 0.019) with an increased risk for A in the dominant model (OR: 1.77, CI: 1.020-3.084, p= 0.042); also concentrations of ApoA-I for A/A were lower in comparison with G/A (p = 0.038) and LDL-C and HDL-C levels were lower in G/A respecting to G/G carriers. 83 C> T polymorphism of APOA1: for DI individuals: HDL-C was lower in T/T respecting to C/C and triglyceride levels were lower in C/T respect to C/C carriers. Conclusions The -75 G>A APOA1 polymorphism could be considered as a susceptibility factor for Myocardial Infarction in individuals with T2DM and 2488 C>T APOB polymorphism is associated with changes in HDL-C and LDL-C and triglycerides in the same group.roup.
No takes yet. Share an insight, caveat, or question.
Casillas et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: